福瑞股份收盘上涨3.04%，滚动市盈率110.92倍，总市值110.03亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Furuya Co., which has a current PE ratio of 110.92, marking a new low in 178 days, with a total market capitalization of 11.003 billion yuan [1][2] - Furuya Co. operates in the medical device industry, specifically focusing on liver disease-related pharmaceuticals, diagnostic equipment, and medical services, with its main product being the Compound Turtle Shell Soft Liver Tablets [1] - As of the first quarter of 2025, Furuya Co. reported a revenue of 330 million yuan, a year-on-year increase of 2.35%, and a net profit of 28.637 million yuan, reflecting a year-on-year decrease of 32.97%, with a gross profit margin of 76.76% [1] Group 2 - In comparison to the industry, Furuya Co.'s PE ratio is significantly higher than the industry average of 53.47 and the median of 37.00, ranking it 105th among its peers [1][2] - The company has 13 institutional investors holding a total of 6.5628 million shares, with a combined market value of 213 million yuan [1]